Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00413829 | Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) | PHASE2 | COMPLETED | 20 | — | — | Oct 1, 2006 | Mar 1, 2008 | Jan 14, 2010 | 1 | Switzerland |
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Intravitreal ranibizumab with photodynamic therapy | DRUG | Intravitreal injection, photodynamic therapy |
Inclusion Criteria: * Patients 50 years of age or greater * Patients with subfoveal choroidal neovascularization lesions secondary to AMD, either predominantly classic, occult, or minimally classic. * CNV lesion in the study eye is ≤5400 microns in greatest linear dimension * Patients who have a be...